Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administra...

Full description

Bibliographic Details
Main Authors: Wenjie Liu, Gengwei Huo, Peng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Public Health
Subjects:
cost-effectiveness analysis
brigatinib
lorlatinib
ALK
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2024.1213318/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2024.1213318/full

Similar Items